A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Status: Recruiting
Location: See all (53) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Participant has a primary diagnosis of schizophrenia
• Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
• Participant must reside in a stable housing situation
Locations
United States
Arkansas
Neurocrine Clinical Site
RECRUITING
Bryant
Neurocrine Clinical Site
RECRUITING
Little Rock
California
Neurocrine Clinical Site
RECRUITING
Chino
Neurocrine Clinical Site
RECRUITING
Culver City
Neurocrine Clinical Site
RECRUITING
Garden Grove
Neurocrine Clinical Site
RECRUITING
La Habra
Neurocrine Clinical Site
RECRUITING
Lemon Grove
Neurocrine Clinical Site
RECRUITING
Oceanside
Neurocrine Clinical Site
RECRUITING
Pico Rivera
Neurocrine Clinical Site
RECRUITING
Riverside
Neurocrine Clinical Site
RECRUITING
San Diego
Neurocrine Clinical Site
RECRUITING
Sherman
Neurocrine Clinical Site
RECRUITING
Torrance
Neurocrine Clinical Site
RECRUITING
West Hills
Florida
Neurocrine Clinical Site
RECRUITING
Atlantis
Neurocrine Clinical Site
RECRUITING
Aventura
Neurocrine Clinical Site
RECRUITING
Doral
Neurocrine Clinical Site
RECRUITING
Hollywood
Neurocrine Clinical Site
RECRUITING
Maitland
Neurocrine Clinical Site
RECRUITING
Miami
Neurocrine Clinical Site
RECRUITING
Miami Lakes
Neurocrine Clinical Site
RECRUITING
Tampa
Neurocrine Clinical Site
RECRUITING
West Palm Beach
Georgia
Neurocrine Clinical Site
RECRUITING
Atlanta
Neurocrine Clinical Site
RECRUITING
Atlanta
Neurocrine Clinical Site
RECRUITING
Decatur
Neurocrine Clinical Sites
RECRUITING
Peachtree Corners
Illinois
Neurocrine Clinical Site
RECRUITING
Chicago
Massachusetts
Neurocrine Clinical Site
RECRUITING
Boston
Neurocrine Clinical Site
RECRUITING
Watertown
Maryland
Neurocrine Clinical Site
RECRUITING
Gaithersburg
Missouri
Neurocrine Clinical Site
RECRUITING
St Louis
Mississippi
Neurocrine Clinical Site
RECRUITING
Flowood
New Jersey
Neurocrine Clinical Site
RECRUITING
Marlton
New York
Neurocrine Clinical Site
RECRUITING
Cedarhurst
Neurocrine Clinical Site
RECRUITING
New York
Neurocrine Clinical Site
RECRUITING
New York
Neurocrine Clincial Site
RECRUITING
Staten Island
Neurocrine Clinical Sites
RECRUITING
The Bronx
Ohio
Neurocrine Clinical Sites
RECRUITING
North Canton
Pennsylvania
Neurocrine Clinical Site
RECRUITING
Philadelphia
Texas
Neurocrine Clinical Site
RECRUITING
Austin
Neurocrine Clinical Site
RECRUITING
Desoto
Neurocrine Clinical Site
RECRUITING
Houston
Utah
Neurocrine Clinical Site
RECRUITING
Orem
Neurocrine Clinical Sites
RECRUITING
Orem
Washington
Neurocrine Clinical Site
RECRUITING
Bellevue
Other Locations
Bulgaria
Neurocrine Clinical Site
WITHDRAWN
Veliko Tarnovo
Neurocrine Clinical Site
RECRUITING
Vratsa
Romania
Neurocrine Clinical Site
RECRUITING
Brasov
Neurocrine Clinical Site
RECRUITING
Bucharest
Neurocrine Clinical Site
RECRUITING
Sânpetru
Serbia
Neurocrine Clinical Site
RECRUITING
Belgrade
Contact Information
Primary
Neurocrine Medical Information Call Center
medinfo@neurocrine.com
877-641-3461
Time Frame
Start Date: 2025-07-11
Estimated Completion Date: 2031-12
Participants
Target number of participants: 800
Treatments
Experimental: NBI-1117568
Participants will receive NBI-1117568 once daily (QD) orally for up to 36 months.
Related Therapeutic Areas
Sponsors
Leads: Neurocrine Biosciences